RU2010114005A - APPLICATION OF A COMBINATION OF THYMOSINE BETA 4 PEPTIDES AND THE PEPTIDE INDUCING DELTA-SON AS A THERAPEUTIC MEDICINE - Google Patents
APPLICATION OF A COMBINATION OF THYMOSINE BETA 4 PEPTIDES AND THE PEPTIDE INDUCING DELTA-SON AS A THERAPEUTIC MEDICINE Download PDFInfo
- Publication number
- RU2010114005A RU2010114005A RU2010114005/15A RU2010114005A RU2010114005A RU 2010114005 A RU2010114005 A RU 2010114005A RU 2010114005/15 A RU2010114005/15 A RU 2010114005/15A RU 2010114005 A RU2010114005 A RU 2010114005A RU 2010114005 A RU2010114005 A RU 2010114005A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- glu
- lys
- diseases
- combination according
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 3
- 230000001939 inductive effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 9
- 239000000203 mixture Substances 0.000 claims abstract 7
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 5
- 208000035473 Communicable disease Diseases 0.000 claims abstract 5
- 206010016654 Fibrosis Diseases 0.000 claims abstract 5
- 208000019693 Lung disease Diseases 0.000 claims abstract 5
- 201000011510 cancer Diseases 0.000 claims abstract 5
- 230000004761 fibrosis Effects 0.000 claims abstract 5
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 5
- 230000004770 neurodegeneration Effects 0.000 claims abstract 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 208000016097 disease of metabolism Diseases 0.000 claims abstract 3
- 208000019622 heart disease Diseases 0.000 claims abstract 3
- 208000015181 infectious disease Diseases 0.000 claims abstract 3
- 239000007788 liquid Substances 0.000 claims abstract 3
- 208000030159 metabolic disease Diseases 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims abstract 3
- 208000019553 vascular disease Diseases 0.000 claims abstract 3
- 206010000234 Abortion spontaneous Diseases 0.000 claims abstract 2
- 208000011231 Crohn disease Diseases 0.000 claims abstract 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims abstract 2
- 241000590002 Helicobacter pylori Species 0.000 claims abstract 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims abstract 2
- 206010039710 Scleroderma Diseases 0.000 claims abstract 2
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 claims abstract 2
- 102100035000 Thymosin beta-4 Human genes 0.000 claims abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract 2
- 230000001154 acute effect Effects 0.000 claims abstract 2
- 210000004204 blood vessel Anatomy 0.000 claims abstract 2
- 239000000872 buffer Substances 0.000 claims abstract 2
- 230000002650 habitual effect Effects 0.000 claims abstract 2
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- 210000003734 kidney Anatomy 0.000 claims abstract 2
- 229940126601 medicinal product Drugs 0.000 claims abstract 2
- 230000004060 metabolic process Effects 0.000 claims abstract 2
- 208000015994 miscarriage Diseases 0.000 claims abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 2
- 208000011906 peptic ulcer disease Diseases 0.000 claims abstract 2
- 230000002265 prevention Effects 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 201000000306 sarcoidosis Diseases 0.000 claims abstract 2
- 208000000995 spontaneous abortion Diseases 0.000 claims abstract 2
- 108010079996 thymosin beta(4) Proteins 0.000 claims abstract 2
- 201000008827 tuberculosis Diseases 0.000 claims abstract 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
Abstract
1. Сочетание пептидов Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH (тимозин бета4) и Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH или их солей или гидратов. ! 2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%. ! 3. Сочетание по п.1 для применения в лекарственном средстве. ! 4. Применение сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 5. Применение сочетания по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из болезни Крона, индуцированной Helicobacter pylori язвенной болезни, острого отторжения аллотрансплантата почки, необъяснимого привычного выкидыша, туберкулеза, рассеянного склероза, склеродермии, диабета типа 1, ревматоидного артрита, саркоидоза, аутоиммунного тиреоидита и/или увеита. ! 6. Применение сочетания по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 7. Применение сочетания по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава. ! 8. Фармацевтическая композиция, содержащая сочетание по п.1 или 2, по меньшей мере, совместно с одним фармацевтически приемл 1. Peptide combination Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr- Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH (thymosin beta4) and Trp- Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH or their salts or hydrates. ! 2. The combination according to claim 1, where the peptides are contained in combination in an amount of from 30 wt.% To 70 wt.% To 70 wt.% To 30 wt.%. ! 3. The combination according to claim 1 for use in a medicinal product. ! 4. The use of the combination according to claim 1, or 2, or 3 to obtain a pharmaceutical composition for the treatment and / or prevention of a malignant tumor, autoimmune diseases, fibrosis, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and diseases metabolism. ! 5. The use of the combination according to claim 4, where the malignant tumor, autoimmune disease, fibrosis, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and blood vessel disease or metabolic disease are selected from Crohn's disease induced by Helicobacter pylori peptic ulcer disease, acute rejection of a kidney allograft, unexplained habitual miscarriage, tuberculosis, multiple sclerosis, scleroderma, type 1 diabetes, rheumatoid arthritis, sarcoidosis, autoimmune thyroiditis and / or uv eita. ! 6. The use of the combination according to claim 1 or 2 to obtain a composition for oral administration to newborns, toddlers and / or preschool children. ! 7. The use of the combination according to claim 1 or 2 to obtain a lyophilized composition or a buffer liquid composition. ! 8. A pharmaceutical composition comprising a combination according to claim 1 or 2, at least in conjunction with one pharmaceutically acceptable
Claims (13)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07017751.4 | 2007-09-11 | ||
| EP07017753.0 | 2007-09-11 | ||
| EP07017751 | 2007-09-11 | ||
| EP07017753 | 2007-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010114005A true RU2010114005A (en) | 2011-10-20 |
Family
ID=40452597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010114005/15A RU2010114005A (en) | 2007-09-11 | 2008-09-09 | APPLICATION OF A COMBINATION OF THYMOSINE BETA 4 PEPTIDES AND THE PEPTIDE INDUCING DELTA-SON AS A THERAPEUTIC MEDICINE |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100210540A1 (en) |
| EP (1) | EP2205266A2 (en) |
| JP (1) | JP2010539071A (en) |
| KR (1) | KR20100056524A (en) |
| AU (1) | AU2008297426A1 (en) |
| CA (1) | CA2699026A1 (en) |
| RU (1) | RU2010114005A (en) |
| WO (1) | WO2009033814A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012126047A1 (en) * | 2011-03-18 | 2012-09-27 | Adistem Ltd | Agent and method for treating pain and reducing inflammation |
| JP2021504349A (en) * | 2017-11-24 | 2021-02-15 | ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． | A composition for promoting goblet cell proliferation or mucin secretion containing thymosin β4 or a derivative thereof as an active ingredient. |
| CN110279702B (en) * | 2019-07-18 | 2022-09-02 | 西安交通大学医学院第一附属医院 | Application of bile acid derivative in medicine for preventing and treating atherosclerosis |
| KR20220140549A (en) * | 2020-02-13 | 2022-10-18 | 에이치엘비테라퓨틱스 주식회사 | Compositions and methods for treating or preventing pruritus |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1188989A (en) * | 1981-05-21 | 1985-06-18 | Richard R. Scherschlicht | Nonapeptide for the treatment of drug withdrawal symptoms |
| RU2070054C1 (en) * | 1993-05-21 | 1996-12-10 | Марина Геннадьевна Маклецова | Agent for burn disease treatment |
| US5536815A (en) * | 1994-03-31 | 1996-07-16 | Research Corporation Technologies, Inc. | Cyclopropyl based O- and N- and S-protecting groups |
| WO1996011016A1 (en) * | 1994-10-06 | 1996-04-18 | Alpha 1 Biomedicals, Inc. | TREATMENT OF OBSTRUCTIVE AIRWAY DISEASE BY ADMINISTERING THYMOSIN β4, OR COADMINISTRATION OF THYMOSIN β4 AND DNase I |
| RU2099078C1 (en) * | 1994-12-08 | 1997-12-20 | Акционерное общество закрытого типа "КОМКОН" | Agent showing antistress, stress-protecting, nootropic, antialcoholic, antinarcotic effect, methods of prophylaxis and treatment using thereof |
| CA2338928A1 (en) * | 1998-07-30 | 2000-02-10 | Hynda K. Kleinman | Thymosin .beta.4 promotes wound repair |
| ID30518A (en) * | 1999-02-05 | 2001-12-13 | Univ Manchester | MANAGEMENT SETTINGS |
| DE10014007A1 (en) * | 2000-03-22 | 2001-10-11 | Strathmann Ag & Co | Medicament for pulmonary or intranasal administration, useful for treating withdrawal symptoms, sleeping disorders or stress, comprises delta-sleep inducing peptide |
| TWI353849B (en) * | 2002-01-25 | 2011-12-11 | Us Gov Health & Human Serv | Methods and compositions for the promotion of hair |
| EP2266595A3 (en) * | 2002-02-06 | 2011-07-06 | Regenerx Biopharmaceuticals, Inc. | Treatment of infections and other disorders |
| WO2003086449A1 (en) * | 2002-04-12 | 2003-10-23 | Yale University | ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN β 4 |
-
2008
- 2008-09-09 RU RU2010114005/15A patent/RU2010114005A/en not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/008162 patent/WO2009033814A2/en active Application Filing
- 2008-09-09 AU AU2008297426A patent/AU2008297426A1/en not_active Abandoned
- 2008-09-09 US US12/677,804 patent/US20100210540A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005673A patent/KR20100056524A/en not_active Application Discontinuation
- 2008-09-09 EP EP08802625A patent/EP2205266A2/en not_active Withdrawn
- 2008-09-09 CA CA2699026A patent/CA2699026A1/en not_active Abandoned
- 2008-09-09 JP JP2010523444A patent/JP2010539071A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009033814A3 (en) | 2009-07-09 |
| JP2010539071A (en) | 2010-12-16 |
| CA2699026A1 (en) | 2009-03-19 |
| EP2205266A2 (en) | 2010-07-14 |
| US20100210540A1 (en) | 2010-08-19 |
| KR20100056524A (en) | 2010-05-27 |
| AU2008297426A1 (en) | 2009-03-19 |
| WO2009033814A2 (en) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010114018A (en) | APPLICATION OF THYMOSINE BETA 4 PEPTID INDIVIDUALLY OR IN COMBINATION WITH CECROPINE A AS A THERAPEUTIC | |
| RU2010114049A (en) | CGRP AS A THERAPEUTIC | |
| RU2010114044A (en) | APPLICATION OF PROTEIN BAND 3 (824-829) AND / OR THE INHIBITION FACTOR OF MELANOTROPINE RELEASE AS A THERAPEUTIC AGAINST TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION | |
| RU2010113986A (en) | APPLICATION OF A PEPTIDE AS A THERAPEUTIC | |
| RU2010113978A (en) | APPLICATION Gly-Pro-Glu-OH (GPE) AS A THERAPEUTIC | |
| RU2010113972A (en) | APPLICATION OF CNP-22 SEPARATELY OR IN COMBINATION WITH PHYSALEMINE AS A THERAPEUTIC MEDICINE | |
| RU2010113964A (en) | APPLICATION OF SOMATOSTATIN-14 AS A THERAPEUTIC | |
| RU2010114031A (en) | PROADRENEDOMEDULLIN INDIVIDUALLY OR IN COMBINATION WITH BIG GASTRIN I AS A THERAPEUTIC MEDICINE | |
| RU2010114002A (en) | APPLICATION OF THE MELANOTROPINE RELEASE INHIBITION FACTOR AS A THERAPEUTIC IN THE TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION | |
| RU2010114000A (en) | USE OF NEUROPEPTIDE SF INDIVIDUALLY OR IN COMBINATION WITH GLP-2 AS A THERAPEUTIC | |
| RU2010114051A (en) | APPLICATION OF GRF-1 (1-29) AND CORTICOLIBERIN AS A THERAPEUTIC | |
| RU2010114014A (en) | APPLICATION OF GLUCAGON (1-29) SEPARATELY OR IN COMBINATION WITH NEUROPEPTIDE W30 AS A THERAPEUTIC MEDICINE | |
| RU2010114030A (en) | APPLICATION OF A PEPTIDE AS A THERAPEUTIC | |
| RU2010113989A (en) | APPLICATION OF A PEPTIDE AS A THERAPEUTIC | |
| RU2010113992A (en) | UROCORTIN AND CORTICOLIBERIN USE AS A THERAPEUTIC | |
| RU2010113994A (en) | HUMAN PANCREATIC POLYPEPTIDE USE AS A THERAPEUTIC MEDICINE | |
| RU2010114039A (en) | USE OF OCTREOTIDE AS A THERAPEUTIC | |
| RU2010114005A (en) | APPLICATION OF A COMBINATION OF THYMOSINE BETA 4 PEPTIDES AND THE PEPTIDE INDUCING DELTA-SON AS A THERAPEUTIC MEDICINE | |
| RU2010114035A (en) | APPLICATION OF RFRP INDIVIDUALLY OR IN COMBINATION WITH NEUROKININ AS A THERAPEUTIC | |
| RU2010114037A (en) | APPLICATION OF PROTEIN BAND 3 AND RASAR-27 AS A THERAPEUTIC MEDICINE | |
| RU2010114060A (en) | APPLICATION OF A PEPTIDE AS A THERAPEUTIC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110912 |